×

Equipment and Services Health Care Equipment and Supplies

  • LONDON, Aug 21- Britain's Creo Medical Group said its device to remove cancerous lesions in the bowel during an endoscopy had received U.S. approval much quicker than it planned, shaking up a timetable that had been focused on a European launch. The company, which listed late last year, said the U.S. Food and Drug Administration had cleared its Speedboat RS2 device...

  • NEW DELHI, Aug 16- India has capped prices of orthopaedic knee implants, in the country's latest move to bring down prices of medical devices. India's drug pricing authority said on Wednesday that orthopaedic implants in India had unjustified, unreasonable and irrationally high trade margins, leading to exorbitant pricing. Major international...

  • NEW DELHI, Aug 16- India has capped prices of orthopaedic knee implants, in the country's latest move to bring down prices of medical devices. India's drug pricing authority said on Wednesday that orthopaedic implants in India had unjustified, unreasonable and irrationally high trade margins, leading to exorbitant pricing. Major pharmaceutical companies...

  • NEW DELHI, Aug 16- India has capped prices of orthopaedic knee implants, in the country's latest move to bring down prices of medical devices. India's drug pricing authority said on Wednesday that orthopaedic implants in India had unjustified, unreasonable and irrationally high trade margins, leading to exorbitant pricing. Major pharmaceutical companies...

  • NEW DELHI, Aug 16- India has capped prices of orthopedic knee implants, in the country's latest move to bring down prices of medical devices. India's drug pricing authority said on Wednesday that orthopedic implants in India had unjustified, unreasonable and irrationally high trade margins, leading to exorbitant pricing. Major pharmaceutical companies have...

  • NEW DELHI, Aug 16- India has capped prices of orthopedic knee implants, in the country's latest move to bring down prices of medical devices. India's drug pricing authority said on Wednesday that orthopedic implants in India had unjustified, unreasonable and irrationally high trade margins, leading to exorbitant pricing. Major pharmaceutical companies have...

  • Cramer Remix: 3 red-hot stocks ready to roar higher

    Jim Cramer crowned three medical device players as winners with plenty more room to run.

  • Jim Cramer on Mad Money.

    Jim Cramer crowned three medical device players as winners with plenty more room to run.

  • Stryker CEO: For us it's always about innovation in medtech

    Kevin Lobo, Stryker CEO, talks the company's mission to provide high-tech, innovative devices for treating patients, including robotic assistance in the operating room.

  • REPUBLICAN SENATE HEALTHCARE BILL REPEALS MEDICAL DEVICES TAX THROUGH DEC. 31, 2020.

  • To bolster its position in the TAVR market in Europe, Boston Scientific in May bought Swiss medical device maker Symetis SA- the fourth-largest player in the multi-billion dollar market- for $435 million. The deal came after Boston Scientific's February recall of its Lotus heart valve devices from Europe and other regions following reports of a faulty...

  • Sales in Boston Scientific's cardiovascular unit- its biggest by revenue- rose 4.7 percent to $876 million in the second quarter ended June 30. Boston Scientific, which closed a $435 million acquisition of Swiss medical device maker Symetis SA in May, posted net profit of $146 million, or 11 cents per share, compared with a net loss of $207 million, or 15 cents per...

  • July 27- Medical device maker Boston Scientific Corp on Thursday posted a profit in the second quarter compared with a year-ago loss, helped by higher sales as well as lower litigation-related expenses. The company posted a net profit of $146 million, or 11 cents per share in the quarter ended June 30, compared with a net loss of $207 million, or 15 cents per share, a...

  • July 20- Abbott Laboratories on Thursday raised its full-year adjusted profit forecast as the diversified healthcare company gains from its $25 billion acquisition of medical devices maker St. The company raised its full-year adjusted earnings from continuing operations by 3 cents to a range of $2.43 per share to $2.53 per share. Abbott, which agreed to buy...

  • Cramer Remix: Snap is the No. 1 reason to own Facebook

    Jim Cramer broke down his strategy to why Snap fell out of his favor.

  • Jim Cramer on the set of Mad Money.

    Jim Cramer broke down his strategy to why Snap fell out of his favor.

  • Listerine, a Johnson & Johnson product.

    Johnson & Johnson raised its full-year profit forecast and reported better-than-expected quarterly earnings, helped by strong demand for its newer products.

  • Cramer Remix: Why it’s still worth owning Procter & Gamble

    Jim Cramer gave his take on how shareholders should play the proxy battle occurring between Procter & Gamble and Nelson Peltz.

  • Jim Cramer on "Mad Money"

    Jim Cramer gave his take on how shareholders should play the proxy battle occurring between Procter & Gamble and Nelson Peltz.

  • Cramer explains why CEO departures are not always bad for companies

    Jim Cramer says the case of medical device maker Zimmer Biomet proves that leadership shakeups are not always negative for the companies involved.